Senior Medical Director - Early-Stage Clinical Development
$346k - $397k+ Equity awards
Senior
MD
Redwood City, CA, USA
HybridOn-site at the Redwood City headquarters.
Biology & Biotech
About the job
Requirements
- An MD is required; oncology training is preferred.
- At least 7 years of experience in clinical development in the pharmaceutical or biotechnology industry and/or an academic or other clinical-trial setting; some early-phase drug-development experience and understanding is preferred.
- Extensive experience with data-analysis, interpretation, and clinical-relevance principles and techniques in the pharmaceutical or biotechnology industry.
- Experience independently generating trial designs; writing or amending protocols and informed consent forms; constructing appropriate case report forms; and coordinating cross-functionally.
- In-depth therapeutic-area expertise and relevant clinical-trial experience, or clear ability to adapt transferable skills.
- Strong knowledge of medical aspects of Good Clinical Practice, International Council for Harmonisation guidelines, and Food and Drug Administration, European Medicines Agency, and other relevant guidelines and regulations.
- Ability to work effectively and efficiently within cross-functional drug-development teams and integrate multiple perspectives into the clinical development plan.
- Experience authoring regulatory briefing packages, writing responses to health-authority questions, and contributing to strategic approaches and cross-functional coordination for regulatory activities and interactions.
- Demonstrated success driving cross-functional study-level strategy, including study design, feasibility, timeline and budget projections, and protocol amendment requirements; ability to drive discussion at internal decision-making bodies and governance forums.
- Ability to build and maintain relationships with external key opinion leaders and contribute to engagement through advisory boards, individual engagements, and steering committees to optimize clinical programs.
- Experience engaging investigators to optimize clinical-trial conduct, including presenting at investigator meetings.
- Experience mentoring clinical scientists and experience or clear potential as an effective line manager.
- Ability to build and maintain relationships with internal and external stakeholders.
- Strategic thinking and analytical skills, including making data-driven decisions, recognizing trade-offs, and setting priorities and goals.
- Strong written and business-presentation skills.
- Ability to anticipate needs and assess and manage business and organizational risks.
Responsibilities
- Lead clinical-science and medical aspects of clinical-development strategy and documentation.
- Represent the clinical development plan on teams, sub-teams, and forums; oversee study-site personnel training; serve as the program-level point of contact for clinical-development-plan questions; and oversee medical and safety data reviews and study reporting.
- Potentially take assignments on complex, high-priority strategic studies and perform the responsibilities independently with self-directed leadership.
- Align cross-functional efforts with scientific, regulatory, and commercial objectives while executing the clinical development plan.
- Lead, mentor, and contribute to a cross-functional clinical-development team.
- Oversee clinical-trial design and execution, including site selection, patient recruitment, data management, and regulatory compliance.
- Establish and maintain relationships with clinical investigators, regulatory agencies, and key stakeholders.
- Gather, analyze, and interpret clinical data, providing strategic insights to inform decisions and guide program development.
- Manage clinical-development timelines, allocate resources, and achieve milestones.
- Stay current with scientific advances and regulatory trends in clinical development.
- Potentially manage multiple direct reports.
Desired Qualifications
- Oncology training; some experience in and understanding of early-phase drug development.
- Significant contributions to conception, conduct, and delivery of clinical development plans, including alignment with scientific governance.
- Experience enhancing or developing core and sub-team processes, structures, systems, tools, and other resources in the pharmaceutical or biotechnology industry.
- Led or supported clinical-development contributions to major regulatory submissions, including Investigational New Drug submissions for first-in-human studies, end-of-Phase 2 briefing books, Pediatric Investigation Plans or Pediatric Study Plans, label negotiation, Breakthrough Therapy Designation, or Accelerated Review.
- Ability to present clinical-development aspects of programs to major health authorities such as the Food and Drug Administration and European Medicines Agency by teleconference or in person; experience leading health-authority interactions.
- Ability to establish clinical-development strategies for Clinical Trial Application or Ethics Committee submissions and responses to health-authority questions.
- Collaborative work on enterprise-level strategic initiatives with internal and external partners, including investigators, clinicians, scientists, key opinion leaders, development, research, business development, commercial, and legal groups, with demonstrable outcomes supporting strategic goals.
- Experience demonstrating courage and conviction and resolving conflicts.
About the company
Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2014
Get referred to Revolution Medicines
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approved RASONQUE on August 26, 2026, six months ahead of deadline.
- RASolute 302 cut death risk 60% and doubled median overall survival to 13.2 months.
- Royalty Pharma's June 2025 $2 billion package funds commercialization and global expansion through 2027.
What critics are saying
- RASONQUE costs $39,800 monthly, inviting Medicare and commercial payer restrictions in 2026.
- Revenue still depends overwhelmingly on one launch; any RASONQUE setback crushes the company.
- AstraZeneca, Amgen, and Mirati pressure RAS programs; resistance or safety issues can erase the franchise.
What makes Revolution Medicines unique
- RASONQUE became the first approved broad RAS(ON) inhibitor on August 26, 2026.
- Revolution Medicines avoids companion diagnostics and treats metastatic PDAC with or without RAS mutations.
- Its pipeline spans daraxonrasib, elironrasib, and zoldonrasib across pancreatic, lung, and colorectal cancers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Company Equity